Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -42.67% is 85% above its 5-year average of -281.82%, near the high end of its 5-year range (-1091.67%–-42.67%).
As of the fiscal period ended Tuesday, March 31, 2026. 49.99% above its 12-month average of -85.33%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-03-31): -30.33%.
RETURN ON ASSETS (ROA)
-42.67%
RETURN ON ASSETS (ROA) AVG TTM
-85.33%
RETURN ON ASSETS (ROA) AVG 3Y
-379.34%
RETURN ON ASSETS (ROA) AVG 5Y
-281.82%
RETURN ON ASSETS (ROA) AVG 10Y
-235.98%
RETURN ON ASSETS (ROA) AVG 15Y
-67.56%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+49.99%
CURRENT VS 3Y AVG
+88.75%
CURRENT VS 5Y AVG
+84.86%
CURRENT VS 10Y AVG
+81.92%
CURRENT VS 15Y AVG
+36.84%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.84%
median of 752 covered companies
CURRENT VS SECTOR MEDIAN
-38.34%
vs the sector median at left
OKYO Pharma Limited
Market Cap
$56.98M
Return on Assets (ROA)
-42.67%
TTM Avg
-85.33%
3Y Avg
-379.34%
5Y Avg
-281.82%
Market Cap
$57.54M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$58.57M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$59.75M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$59.66M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$53.22M
Return on Assets (ROA)
-48.49%
TTM Avg
-50.18%
3Y Avg
-39.97%
5Y Avg
-38.29%
Market Cap
$60.08M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$53.69M
Return on Assets (ROA)
-34.52%
TTM Avg
-27.74%
3Y Avg
-32.72%
5Y Avg
-28.49%
Market Cap
$53.62M
Return on Assets (ROA)
-54.01%
TTM Avg
-81.00%
3Y Avg
-93.15%
5Y Avg
-65.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.98M | -42.67% | -85.33% | -379.34% | -281.82% |
| Boundless Bio, Inc. (BOLD)vs › | $57.54M | -37.05% | -34.36% | -41.63% | -37.74% |
| Fractyl Health, Inc. (GUTS)vs › | $58.57M | -128.88% | -89.84% | -89.26% | -80.42% |
| PDS Biotechnology Corporation (PDSB)vs › | $59.75M | -382.32% | -98.02% | -80.35% | -65.77% |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.66M | -393.68% | -194.68% | -123.06% | -102.52% |
| Aldeyra The (ALDX)vs › | $53.22M | -48.49% | -50.18% | -39.97% | -38.29% |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.08M | -118.15% | -138.13% | -224.99% | -221.92% |
| ImageneBio Inc (IMA)vs › | $53.69M | -34.52% | -27.74% | -32.72% | -28.49% |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | -54.01% | -81.00% | -93.15% | -65.68% |
| Adicet Bio, Inc. (ACET)vs › | $60.69M | -66.80% | -56.95% | -50.95% | -40.99% |
ROA
-42.7%
ROE
-72.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -42.67% |
| 2025-03-31 | -127.98% |
| 2024-03-31 | -1091.67% |
| 2023-03-31 | -255.04% |
| 2022-03-31 | -126.28% |
| 2021-03-31 | -47.30% |
| 2020-03-31 | -258.14% |
| 2019-03-31 | -644.20% |
| 2018-03-31 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-03-31 | -2.55% |
| 2015-03-31 | -24.25% |
| 2014-03-31 | -29.54% |
| 2013-03-31 | -10.71% |
| 2012-03-31 | -11.38% |
| 2011-03-31 | -10.05% |
| 2010-03-31 | 23.41% |
| 2009-03-31 | 37.46% |
| 2008-03-31 | -10.78% |
